Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)
Key Insights
- The projected fair value for Zhangzhou Pientzehuang Pharmaceutical is CN¥231 based on 2 Stage Free Cash Flow to Equity
- Current share price of CN¥202 suggests Zhangzhou Pientzehuang Pharmaceutical is potentially trading close to its fair value
- The CN¥264 analyst price target for 600436 is 14% more than our estimate of fair value
Does the September share price for Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
View our latest analysis for Zhangzhou Pientzehuang Pharmaceutical
What's The Estimated Valuation?
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥3.61b | CN¥4.18b | CN¥4.80b | CN¥5.41b | CN¥5.87b | CN¥6.27b | CN¥6.62b | CN¥6.93b | CN¥7.22b | CN¥7.50b |
Growth Rate Estimate Source | Analyst x2 | Analyst x2 | Analyst x2 | Analyst x2 | Est @ 8.48% | Est @ 6.79% | Est @ 5.61% | Est @ 4.78% | Est @ 4.20% | Est @ 3.80% |
Present Value (CN¥, Millions) Discounted @ 6.8% | CN¥3.4k | CN¥3.7k | CN¥3.9k | CN¥4.2k | CN¥4.2k | CN¥4.2k | CN¥4.2k | CN¥4.1k | CN¥4.0k | CN¥3.9k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥40b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.8%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥7.5b× (1 + 2.9%) ÷ (6.8%– 2.9%) = CN¥194b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥194b÷ ( 1 + 6.8%)10= CN¥100b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥140b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of CN¥202, the company appears about fair value at a 13% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Zhangzhou Pientzehuang Pharmaceutical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Zhangzhou Pientzehuang Pharmaceutical
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Earnings growth over the past year is below its 5-year average.
- Dividend is low compared to the top 25% of dividend payers in the Pharmaceuticals market.
- Annual earnings are forecast to grow for the next 3 years.
- Current share price is below our estimate of fair value.
- Dividends are not covered by cash flow.
- Annual earnings are forecast to grow slower than the Chinese market.
Moving On:
Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Zhangzhou Pientzehuang Pharmaceutical, we've put together three further items you should further research:
- Risks: For example, we've discovered 2 warning signs for Zhangzhou Pientzehuang Pharmaceutical (1 can't be ignored!) that you should be aware of before investing here.
- Future Earnings: How does 600436's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if Zhangzhou Pientzehuang Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600436
Zhangzhou Pientzehuang Pharmaceutical
Engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally.
Flawless balance sheet average dividend payer.